Privacy Policy

Login

Inställningar

Split view

Short keys for navigating in split view

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Dark Mode

Set dark mode to MFN.se

Sound

Plays a notification sound when new press release is published in the current feed

Intresserad av platformen MFN för nyhetsdistribution?

Onsdag 28 Oktober | 18:26:10 Europe / Stockholm

Svenska | English

Investor Relations

Public Relations

Redeye

Bifogade filer

AlzeCure Pharma (Q1 Review): Advancing toward Phase IIa with NeuroRestore ACD856

Prenumeration

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

AlzeCure Pharma (Q1 Review): Advancing toward Phase IIa with NeuroRestore ACD856

2026-05-08 10:16:00

Redeye’s analyst just published a Research Update on AlzeCure Pharma.

Click here to read the article

Make sure to add AlzeCure Pharma to your Watchlist at Redeye and our analysts will notify you if anything relevant happens regarding your companies.

This is a press release from Redeye - Nordic Growth. www.redeye.se